1. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial 
Patrick M. Moriarty, MD, Klaus G. Parhofer, MD, Stephan P. Babirak, MD, PhD, Emil deGoma, MD, P. Barton Duell, MD, Bernd Hohenstein, MD, Wolfgang Ramlow, MD, Vinaya Simha, MD, Elisabeth Steinhagen-Thiessen, MD, Paul D. Thompson, MD, Anja Vogt, MD, Berndt von Stritzky, MD, Yunling Du, PhD, Garen Manvelian, MD 
Journal of Clinical Lipidology 
Volume 10, Issue 3, Pages (May 2016)
DOI: /j.jacl
Copyright © 2016 National Lipid Association Terms and Conditions

2. Figure 1
Study design. *Patients will receive alirocumab 150 mg subcutaneously or placebo Q2W at visits 2 through 10, starting at day 1. †Visits at these times are mandatory for patients undergoing lipoprotein apheresis QW but not for patients undergoing apheresis Q2W. ‡Visits 6 through 10 (as in visits 2 through 5) will each have an optional sub-visit, 6a through 10a, when study drug will not be administered but are mandatory for patients undergoing lipoprotein apheresis QW. ¶All patients will be seen at visit 11 and will complete all end of double-blind treatment period assessments; patients will then undergo dosing procedures for the first visit of the open-label treatment period. D, day; Q2W, every 2 weeks; QW, every week; V, visit; W, week.
Journal of Clinical Lipidology  , DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions